STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
In a setback for Merck, a Dutch court ruled that the company infringed on a patent pertaining to a subcutaneous formulation of its Keytruda cancer treatment and was ordered to halt manufacturing and marketing the medication in several European…
ImpactNotable 33/100
Why it mattersRule-based estimate: no strong signals; trust 8/10.
RegionsGlobal
Published8 h ago (Wed, 07 Oct 2026 14:06:29 GMT)
RetrievedWed, 07 Oct 2026 17:00:27 GMT via rss
ClassifiedWed, 07 Oct 2026 17:00:41 GMT by heuristic
AuthorEd Silverman